Key result
Takotsubo cardiomyopathy in COVID-19 patients was associated with an all-cause mortality of 36.5%, more critical illness, and higher mortality compared to COVID-19 patients without TCM.
Why the study?
COVID-19 has recently been associated with the development of Takotsubo cardiomyopathy, prompting a need to summarize existing evidence and offer future direction for study.
Systematic Review (n=52)
Answers are grounded in this paper and cite their sources.
Takotsubo cardiomyopathy in COVID-19 patients presents with distinct features, including high mortality (36.5%), severe LV dysfunction, and less female predominance compared to typical TCM.
BACKGROUND: COVID-19 has recently been associated with the development of Takotsubo cardiomyopathy (TCM). This scoping review aims to summarize the existing evidence regarding TCM in COVID-19 and offer future direction for study. METHODS: Following the PRISMA Extension for Scoping Reviews, MEDLINE and EMBASE were searched for all peer-reviewed articles with relevant keywords including "Takotsubo", "Stress-induced cardiomyopathy" and "COVID-19" from their inception to September 25, 2021. RESULTS: A total of 40 articles with 52 cases were included. Patients with TCM and COVID-19 showed only slight female predominance (59.6%), median age of 68.5 years, and were mostly of the apical subtype (88.6%). All-cause mortality was 36.5%. The median LVEF was 30%. Compared to those without TCM, those with TCM in COVID-19 had more critical illness, higher mortality, lower LVEF, and higher cardiac and inflammatory biomarkers. Notably, the diagnostic criteria of TCM were considerably different between case reports and observational studies. CONCLUSION: This scoping review identifies that TCM in COVID-19 may have distinct features that distinguish this condition from TCM without COVID-19. Future studies are warranted to help describe risk factors, determine the utility of inflammatory biomarkers and serum catecholamine levels, and establish disease-specific diagnostic criteria.
No takes yet. Share an insight, caveat, or question.
Techasatian et al. (2022) conducted a systematic review in Takotsubo cardiomyopathy in COVID-19 (n=52). Takotsubo cardiomyopathy vs. No Takotsubo cardiomyopathy was evaluated on All-cause mortality. Takotsubo cardiomyopathy in COVID-19 patients was associated with an all-cause mortality of 36.5%, more critical illness, and higher mortality compared to COVID-19 patients without TCM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: